We are pleased to announce our upcoming third annual HMRG European HIV Seminars, focusing this year on ’Changing the Treatment Paradigm’.
With more tools at our disposal than ever before to manage HIV infection, it is important that healthcare and non-healthcare providers involved in HIV care can access up to date, contemporary information on recent advances in HIV and its management in order to deliver the best care possible.
The third annual HMRG European HIV Seminar offers a unique opportunity for physicians both within and outside of the HIV specialist field, allied healthcare professionals and community representatives to assemble and share their perspectives on current challenges on HIV care and prospective developments in the field.
The HMRG European HIV Seminars is a two-day event with seminars delivered by international key opinion leaders in the field covering recent advances relevant to patient care such as novel therapies and treatment approaches, prevention strategies, and developments in HIV cure research. We are excited to have community representatives join our panel this year to offer a patient’s perspective on these and other topics.
This meeting creates a relaxed, informal, yet stimulating atmosphere which will foster excellent discussion and will provide those involved in HIV care an opportunity to update and broaden their knowledge, and ultimately, offer potential networking opportunities.
The meeting venue is the historic Mater Misericordiae University Hospital campus close to the many enjoyable sites of Dublin, a delightful city to visit in early Summer.
We hope you enjoy all that this meeting has to offer and look forward to welcoming you to Dublin in June 2019.
The Organising Committee
Online registration will close on 20th June 5pm. Limited registration places will be available onsite
This meeting has been granted 6 European CME credits (ECMEC®s) by the European Accreditation Council for Continuing Medical Education (EACCME®)
This meeting is supported by educational grants from ViiV Healthcare, Gilead Sciences, Merck Sharp & Dohme and Janssen Sciences Ireland which have taken no role in designing the agenda or educational content of the meeting